Key result
Drug-eluting endovascular therapies cut loss of primary patency ~40% vs. plain angioplasty in CLTI.
Why the study?
Plain old balloon angioplasty in diabetic foot ulcer and chronic limb-threatening ischemia is limited by early restenosis, yet no evidence synthesis had integrated paclitaxel- and sirolimus-based devices individually, head-to-head, or as combined strategies in this population.
Does sirolimus- and paclitaxel-based endovascular therapy after angioplasty reduce loss of primary patency and clinically driven target lesion revascularisation in patients with diabetic foot ulcers and chronic limb-threatening ischemia?
Meta-Analysis (n=1,204)
Yes
Does sirolimus- and paclitaxel-based endovascular therapy after angioplasty reduce loss of primary patency and clinically driven target lesion revascularisation in patients with diabetic foot ulcers and chronic limb-threatening ischemia?
In patients with diabetic foot ulcers and chronic limb-threatening ischemia undergoing angioplasty, both sirolimus- and paclitaxel-based endovascular therapies significantly reduce restenosis and halve clinically driven target lesion revascularization without increasing mortality, with sirolimus demonstrating a superior limb-event profile.
Answers are grounded in this paper and cite their sources.
Drug-eluting therapies merit consideration in DFU/CLTI angioplasty; reinforces RCT evidence for sirolimus- and paclitaxel-based devices.
Introduction: Diabetic foot ulcer (DFU) complicated by chronic limb-threatening ischemia (CLTI) is driven by diffuse, calcified infrapopliteal disease in which plain old balloon angioplasty (POBA) is limited by early restenosis. Paclitaxel-based devices (cytotoxic microtubule stabilisation) and sirolimus-based devices (cytostatic mTOR inhibition) were developed to prevent neointimal hyperplasia, yet no synthesis has integrated both drug platforms—individually, head-to-head, or as complementary (combined) strategies—in diabetic/CLTI populations. We aimed to quantify the clinical outcomes of sirolimus- and paclitaxel-based endovascular therapy after angioplasty in patients with DFU and CLTI. Methods: The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. Eligible designs were randomised controlled trials (RCTs), prospective/retrospective cohort, case–control, cross-sectional and single-arm observational studies enrolling adults with DFU and/or CLTI (enrichment threshold ≥40% CLTI or ≥40% diabetes) treated with sirolimus-eluting stents/balloons (SES/SCB) and/or paclitaxel-coated balloons/eluting stents (PCB/PES) after angioplasty. Systematic reviews were excluded from synthesis and used only in the Discussion. Risk of bias was assessed with RoB 2, ROBINS-I and MINORS. Random-effects (DerSimonian–Laird) risk ratios (RR), mean differences and logit-transformed proportions were pooled; heterogeneity (I², τ², 95% prediction interval), subgroup (drug class), leave-one-out, cumulative, meta-regression and small-study (Egger, Begg) analyses were performed and certainty was graded with GRADE. Results: Thirty-five studies (47 reports) were included: 20 RCTs, 4 non-randomised comparative studies and 11 single-arm cohorts. Compared with non-drug angioplasty/stenting, drug-eluting therapy reduced loss of primary patency (9 RCTs, n = 1204; RR 0.60, 95% CI 0.43–0.82; I² = 78%; number needed to treat ≈ 6), with consistent effects for paclitaxel (RR 0.63, 0.43–0.93) and sirolimus (RR 0.50, 0.35–0.70; P-interaction = 0.37), and reduced clinically driven target lesion revascularisation (7 RCTs, n = 998; RR 0.45, 0.33–0.62; I² = 0%; NNT ≈ 9). Late lumen loss was lower with paclitaxel-coated balloons (MD −0.44 mm, −0.84 to −0.05). Major amputation (RR 0.67, 0.27–1.70) and all-cause mortality (RR 0.90, 0.72–1.12) were not significantly different; the composite major adverse limb event was reduced by sirolimus (SirPAD; RR 0.59, 0.43–0.80) but not by paclitaxel (RR 1.19, 0.75–1.89; P-interaction = 0.012). In head-to-head diabetic/CLTI comparisons, sirolimus-family devices reduced loss of patency versus paclitaxel (RR 0.53, 0.29–0.96) without differences in amputation or mortality. Pooled single-arm cohorts and trial arms showed 6-month patency of 77.1% with sirolimus-coated balloons vs 67.8% with paclitaxel-coated balloons, and wound healing of 81.4% vs 79.7%. No small-study effects were detected. Certainty ranged from moderate (revascularisation) to very low (amputation, head-to-head). Discussion: Both antiproliferative platforms convert angiographic benefit into fewer repeat revascularisations in diabetic CLTI, but neither has yet been proven to reduce limb loss or death. Sirolimus offers a wider therapeutic window, no slow-flow phenomenon and the only randomised reduction in major adverse limb events, whereas paclitaxel carries the longest efficacy record but persistent early-amputation and late-mortality uncertainty. Mechanistic complementarity (G1 versus G2/M arrest; carrier-dependent versus lipophilic retention) supports segment-tailored and bail-out combined use and justifies dual-drug platforms, which remain pre-clinical. Conclusion: In patients with DFU and CLTI undergoing angioplasty, sirolimus- and paclitaxel-based endovascular therapies roughly halve clinically driven revascularisation and reduce restenosis without increasing mortality, with sirolimus showing a more favourable limb-event and safety profile. Adequately powered infrapopliteal RCTs with wound-healing and limb-salvage endpoints, and trials of deliberate sequential or dual-drug strategies, are required.
No takes yet. Share an insight, caveat, or question.
Wirajaya et al. (2026) conducted a meta-analysis in Diabetic foot ulcer and/or chronic limb-threatening ischemia (CLTI) (n=1,204). Sirolimus- and/or paclitaxel-based endovascular therapy (SES/SCB and/or PCB/PES) vs. Non-drug angioplasty/stenting (POBA ± bare-metal stent or uncoated device) was evaluated on Loss of primary patency / binary restenosis (RR 0.60, 95% CI 0.43-0.82). Sirolimus- and paclitaxel-based endovascular therapies reduced loss of primary patency and target lesion revascularisation versus non-drug angioplasty in DFU/CLTI.
Synapse has enriched 10 related papers. Consider them for comparative context: